Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Mineralys Therapeutics Inc (NASDAQ: MLYS) closed at $37.43 up 0.21% from its previous closing price of $37.35. In other words, the price has increased by $0.21 from its previous closing price. On the day, 0.67 million shares were traded. MLYS stock price reached its highest trading level at $37.66 during the session, while it also had its lowest trading level at $36.5.
Ratios:
For a deeper understanding of Mineralys Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 25.50 and its Current Ratio is at 25.50. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 20 ’25 when Slingsby Brian Taylor sold 1,000,000 shares for $43.35 per share. The transaction valued at 43,350,000 led to the insider holds 7,903,838 shares of the business.
Catalys Pacific Fund, LP bought 1,000,000 shares of MLYS for $42,120,000 on Nov 20 ’25. On Nov 11 ’25, another insider, Levy Adam Scott, who serves as the CFO and Secretary of the company, sold 119,524 shares for $44.88 each. As a result, the insider received 5,363,716 and left with 19,396 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 2962208512 and an Enterprise Value of 2368580608.
Stock Price History:
The Beta on a monthly basis for MLYS is 0.44, which has changed by 1.9196568 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $47.65, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is -7.44%, while the 200-Day Moving Average is calculated to be 52.18%.
Shares Statistics:
For the past three months, MLYS has traded an average of 1.54M shares per day and 1798510 over the past ten days. A total of 78.97M shares are outstanding, with a floating share count of 56.37M. Insiders hold about 28.77% of the company’s shares, while institutions hold 79.50% stake in the company. Shares short for MLYS as of 1765756800 were 7948340 with a Short Ratio of 5.16, compared to 1763078400 on 6889251. Therefore, it implies a Short% of Shares Outstanding of 7948340 and a Short% of Float of 12.560001000000002.
Earnings Estimates
The company has 7.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.44 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$2.13 and -$2.57 for the fiscal current year, implying an average EPS of -$2.4. EPS for the following year is -$2.31, with 6.0 analysts recommending between -$1.74 and -$3.03.
